Merck has the first option to negotiate an exclusive license. These preclinical proof-of-principle studies will be conducted using an undisclosed Merck vaccine.
Stanley Erck, president and CEO of Iomai, said: “This agreement with Merck allows us to further evaluate the possible applications of our patch. Our immunostimulant patch has the potential to improve the immune response to a wide variety of vaccines, allowing for more effective vaccines, or vaccines that work at a lower dose.”